GlassScriptPhysician profile
Laura A Ofarrell
NPI 1164977864
$19,614.78
in general payments reported to CMS, 2019-2025
20 companies · $3,171 in 2025
The $3,171 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $8,495 · 2022: $3,106 · 2023: $2,058 · 2024: $2,786 · 2025: $3,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,014.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,276.00 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,195.12 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $903.71 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $859.78 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alkermes, INC. | $788.71 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $628.24 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $605.53 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $579.51 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $476.20 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $429.55 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $180.60 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $157.85 | 2022-2023 | Belsomra |
| Novo Nordisk INC | $150.82 | 2025 | Wegovy, Ozempic |
| Sunovion Pharmaceuticals INC. | $114.57 | 2021-2022 | |
| Lilly USA, LLC | $77.62 | 2025 | Zepbound |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $72.57 | 2021-2022 | |
| Corium, LLC | $43.84 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $38.05 | 2025 | Qelbree |
| Almatica Pharma LLC | $19.69 | 2025 | Loreev Xr |
| Neuronetics, INC. | $16.82 | 2024 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Ofarrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.